Fight Aging! Newsletter, December 19th 2022
In conclusion, p16 deletion or p16 positive cell clearance could be a novel strategy preventing long term HFD-induced skin aging.
Association of LDL-Cholesterol with Mortality
https://www.fightaging.org/archives/2022/12/association-of-ldl-cholesterol-with-mortality/
Researchers here report on a study of LDL-cholesterol and mortality risk in older people. As they note, data on this topic is conflicted once one moves beyond the matter of cardiovascular disease. Over a lifetime, higher LDL-cholesterol makes it easier to reach the tipping point at which cholesterol deposited in blood vessel walls produces e...
Source: Fight Aging! - December 18, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
T Cell Immunotherapy an Improvement Over Checkpoint Inhibition
Researchers here report on the results of a phase III trial of tumor infiltrating leukocyte (TIL) therapy for melanoma. A patient's T cells are multiplied outside the body and then injected, along with chemotherapy beforehand to clear existing T cell populations, and IL-2 delivery afterwards to promote replication of the delivered T cells. It has meaningful side-effects, as do other cancer immunotherapies, but the outcome is an improvement over the present standard approach of checkpoint inhibition for melanoma. Even as better approaches to cancer therapy are in development, such as those based on interference in telomere ...
Source: Fight Aging! - December 14, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Most important cardiotoxicity of immune checkpoint inhibitors – Cardiology MCQ – Answer
Most important cardiotoxicity of immune checkpoint inhibitors – Answer
Cardiotoxicity of immune checkpoint inhibitors – Correct answer: 1. Fulminant myocarditisImmunotherapy with immune checkpoint inhibitors is becoming standard of care for multiple types of malignancies. Important immune checkpoint inhibitors are ipilimumab which acts against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4); nivolumab and pembrolizumab which act against programmed cell death 1 (PD-1) and atezolizumab which targets PD-1 ligand (PD-L1).
Autoimmune fulminant myocarditis has been described in persons treate...
Source: Cardiophile MD - October 4, 2021 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
Newer skin cancer treatments improve prognosis for those with cutaneous melanoma
Cutaneous melanoma, also called malignant melanoma, is the type of skin cancer that is most likely to spread to other parts of the body. Though melanoma accounts for only about 1% of skin cancers, it is responsible for more than 90% of skin cancer-related deaths.
But thanks to developments in skin cancer treatment (mostly in the last decade), patients with melanoma have much better chances of living longer.
What is a melanoma?
Melanoma involves the uncontrolled growth of a type of cell known as a melanocyte. One of the most important functions of a normal melanocyte is to protect your skin from the sun’s damaging ultravi...
Source: Harvard Health Blog - February 3, 2020 Category: Consumer Health News Authors: Dominic Wu, MD Tags: Cancer Skin and Hair Care Source Type: blogs
Fight Aging! Newsletter, January 20th 2020
This study provides strong evidence that following a healthy lifestyle can substantially extend the years a person lives disease-free."
Commentary on Recent Evidence for Cognitive Decline to Precede Amyloid Aggregation in Alzheimer's Disease
https://www.fightaging.org/archives/2020/01/commentary-on-recent-evidence-for-cognitive-decline-to-precede-amyloid-aggregation-in-alzheimers-disease/
I can't say that I think the data presented in the research noted here merits quite the degree of the attention that it has been given in the popular science press. It is interesting, but not compelling if its role is ...
Source: Fight Aging! - January 19, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Cancer Mortality Rates Continue to Fall
That cancer mortality is declining at a time in which the aged segment of the population is growing, and ever more people are overweight and obese, is a testament to (a) improved prevention (largely fewer people smoking, which has a sizable impact on lung cancer incidence and severity) and (b) the ever increasing efficacy of modern cancer treatments, particularly immunotherapies. These newer cancer therapies are still in the comparatively early stages of evolution as a technology platform, and we should expect these gains to continue. The immunotherapies of the 2030s will be very impressive in comparison to those deployed ...
Source: Fight Aging! - January 17, 2020 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Last Month in Oncology with Dr. Bishal Gyawali: April 2019
By BISHAL GYAWALI, MD
Keynote speech on the JAVELIN not going far enough to improve survival
The treatment landscape for metastatic renal-cell carcinoma has changed dramatically with the introduction of immunotherapies. Unfortunately though, we are promoting combinations over single agents without having much idea of added benefit of each drug. This is an important issue because when we combine two drugs, the only thing we are certain of are the added toxicities. PD-1 inhibitor nivolumab had improved OS when given in second line, however nivolumab was tested in combination with ipilimumab (not as a nivolumab monother...
Source: The Health Care Blog - May 10, 2019 Category: Consumer Health News Authors: Christina Liu Tags: Medical Practice Physicians Bishal Gyawali Clinical Trials Oncology PD-1 inhibitor Source Type: blogs
Cancer treatment: Is a clinical trial right for you?
Clinical trials are research studies that test a new drug or therapy in patients who have a disease. These studies are classified as phase I, II, or III depending on their purpose.
Phase I: These initial, small studies test promising new drugs that effectively kill cancer cells in laboratory experiments. The goal is to understand the safe dose and capture early evidence of benefit. Phase I trials may be open to patients with any type of cancer, or only certain types of cancers more likely to respond to specific drugs. Generally, fewer than 50 patients are enrolled.
Phase II: Once a phase I trial identifies a safe dose, ...
Source: Harvard Health Blog - March 22, 2019 Category: Consumer Health News Authors: Guru P. Sonpavde, MD Tags: Breast Cancer Health Treatments Source Type: blogs
Immunotherapy: What you need to know
Not all that long ago, chemotherapy was the only option to treat most advanced (metastatic) cancers. Because these drugs work by destroying rapidly dividing cells, they harm some healthy cells — such as hair follicles — as well as cancer cells. In the past two decades, cancer treatment has been transformed by targeted drugs and the emergence of chemotherapy. Targeted drugs are designed to home in on specific genes or proteins that are altered or overexpressed on cancer cells. Immunotherapy has been very successful for certain types of advanced cancers, such as lung, bladder, and skin cancers.
One form of immunotherapy ...
Source: Harvard Health Blog - January 22, 2019 Category: Consumer Health News Authors: Guru P. Sonpavde, MD Tags: Cancer Immunotherapy Managing your health care Source Type: blogs
Fight Aging! Newsletter, November 19th 2018
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more.
This content is...
Source: Fight Aging! - November 18, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A Popular Science View of Checkpoint Inhibitor Cancer Immunotherapies
Checkpoint inhibitor therapies are a demonstrably successful approach to cancer immunotherapy. They suppress a mechanism that normally restrains immune cells from attacking other cells. This mechanism is abused by cancers, alongside a variety of other ways in which the immune system can be subverted or quieted. Any advanced tumor tends to have evolved into a state in which it is ignored or even helped by the immune system. Checkpoint inhibitor therapies are an improvement on chemotherapy when it comes to the trade-off between harming the cancer and harming the patient, as well as in the odds of success, but still present r...
Source: Fight Aging! - November 13, 2018 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Last Month in Oncology with Dr. Bishal Gyawali
By BISHAL GYAWALI MD
Me-too deja vu
I read the report of a phase 3 RCT of a “new” breast cancer drug but I had the feeling that I had already read this before. Later I realized that this was indeed a new trial of a new drug, but that I had read a very similar report of a very similar drug with very similar results and conclusions. This new drug is a PARP inhibitor called talazoparib and the deja vu was related to another PARP inhibitor drug called olaparib tested in the same patient population of advanced breast cancer patients with a BRCA mutation. The control arms were the same: physician choice of drug, except t...
Source: The Health Care Blog - November 8, 2018 Category: Consumer Health News Authors: matthew holt Tags: Drug Discovery Pharmaceuticals Bishal Gyawali Cancer immunotherapy Oncology Source Type: blogs
The Abscopal Effect
In the waning years of my career as a Nuclear Radiologist, I have become somewhat more jaded than I was as a younger doc. When you see cancer and other diseases fifty times a day, sometimes getting better, sometimes getting worse, that ' s bound to happen. Of course, I ' m far prefer reporting improvement, but relapses are also part of this job. The oncologists wander into the reading room every few minutes, or so it seems, anyway, to look at their patients ' scans (the gantry is generally still warm). If the news is bad, I will tell them in all honesty that I admire the strength it will take to deliver the bad news. On th...
Source: Dalai's PACS Blog - August 19, 2018 Category: Radiology Source Type: blogs
Most important cardiotoxicity of immune checkpoint inhibitors – Cardiology MCQ – Answer
Most important cardiotoxicity of immune checkpoint inhibitors – Answer
Interactive Kindle Edition: Check here for more Cardiology MCQs!
Cardiotoxicity of immune checkpoint inhibitors – Correct answer: 1. Fulminant myocarditis
Immunotherapy with immune checkpoint inhibitors is becoming standard of care for multiple types of malignancies. Important immune checkpoint inhibitors are ipilimumab which acts against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4); nivolumab and pembrolizumab which act against programmed cell death 1 (PD-1) and atezolizumab which targets PD-1 ligand (PD-L1).
Autoimmune fulminan...
Source: Cardiophile MD - March 25, 2018 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
Most important cardiotoxicity of immune checkpoint inhibitors – Cardiology MCQ – Answer
Most important cardiotoxicity of immune checkpoint inhibitors – Answer
Interactive Kindle Edition: Check here for more Cardiology MCQs!
Correct answer: 1. Fulminant myocarditis
Important immune checkpoint inhibitors are ipilimumab which acts against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4); nivolumab and pembrolizumab which act against programmed cell death 1 (PD-1) and atezolizumab which targets PD-1 ligand (PD-L1).
Autoimmune fulminant myocarditis has been described in persons treated with immune checkpoint inhibitors [2]. It is associated with profound hemodynamic compromise progressing to circulato...
Source: Cardiophile MD - March 25, 2018 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs